Systematic review with meta-analysis: Highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 3, 2014, Pages 239-253

  Shin, A ^a   Camilleri, M ^a   Kolar, G ^a   Erwin, P ^b   West, C P ^c   Murad, M H ^c  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARONAPRIDE; PRUCALOPRIDE; SEROTONIN AGONIST; VELUSETRAG;

ABDOMINAL PAIN; ARTICLE; CHRONIC CONSTIPATION; CONSTIPATION; DIARRHEA; DIGESTIVE FUNCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PAC OF SYMPTOMS; PATIENT ASSESSMENT OF CONSTIPATION QUALITY OF LIFE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; STOOL CONSISTENCY; STOOL FREQUENCY; SYMPTOM; SYSTEMATIC REVIEW;

ADULT; AZABICYCLO COMPOUNDS; BENZAMIDES; BENZOFURANS; CHRONIC DISEASE; CONSTIPATION; DEFECATION; HUMANS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUINUCLIDINES; SEROTONIN 5-HT4 RECEPTOR AGONISTS;

EID: 84891887937     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12571     Document Type: Article

References (39)

1. Suares NC, Ford AC,. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 1582-91.
2. Johanson JF, Kralstein J,. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599-608.
3. 4 recepr agonists: similar but no the same. Neurogastroenterol Motil 2008; 20: 99-112.
4. Prins NH, Shankley NP, Welsh NJ, et al,. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000; 129: 1601-8.
5. Briejer MR, Akkermans LM, Schuurkes JA,. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631-51.
6. Drolet B, Khalifa M, Daleau P, et al,. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-10.
7. Mohammad S, Zhou Z, Gong Q, et al,. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534-8.
8. Camilleri M, Deiteren A,. Prucalopride for constipation. Expert Opin Pharmacother 2010; 11: 451-61.
9. Smith JA, Beattie DT, Marquess D, et al,. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 125-37.
10. Beattie DT, Armstrong SR, Shaw JP, et al,. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 139-47.
11. Dennis D, Palme M, Irwin I, et al,. ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology 2004; 126: A641.
12. Tack J, Camilleri M, Chang L, et al,. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012; 35: 745-67.
13. Busti AJ, Murillo JR Jr, Cryer B,. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24: 526-31.
14. Ford AC, Suares NC,. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011; 60: 209-18.
15. Tack J, Corsetti M,. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol 2012; 8: 1327-35.
16. Gatta L, Kerstens R, Scarpignato C,. How effective is prucalopride for the treatment of chronic constipation? A systematic review and meta-analysis. Gastroenterology 2013; 144 (Suppl. 1): S547-8.
17. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O,. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 540-51.
18. Frank L, Kleinman L, Farup C, Taylor L, Miner P,. Jr.Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 870-7.
19. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
20. Higgins J, Altman D,. Cochrane Handbook (Version 5). Sections relating to new risk-of-bias tool. Oxford: Wiley, 2007.
21. Coremans G, Kerstens R, De Pauw M, et al,. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67: 82-9.
22. Ke M, Zou D, Yuan Y, et al,. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012; 24: 999-e541.
23. Camilleri M, Kerstens R, Rykx A, et al,. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344-54.
24. Emmanuel AV, Roy AJ, Nicholls TJ, et al,. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002; 16: 1347-56.
25. Müller-Lissner S, Rykx A, Kerstens R, et al,. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010; 22: 991-8, e255.
26. Bouras EP, Camilleri M, Burton DD, et al,. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-60.
27. 4 agonist with high intrinsic activity, in chronic idiopathic constipation-a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010; 32: 1102-12.
28. Tack J, Van Outryve M, Beyens G, et al,. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-65.
29. Quigley EM, Vandeplassche L, Kerstens R, et al,. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 315-28.
30. Camilleri M, Beyens G, Kerstens R, et al,. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009; 21: 1256-e117.
31. Van Outryve M, Bosseckert H, Bouchoucha M, et al,. Effect of the novel enterokinetic prucalopride, in patients with chronic constipation: a double-blind, placebo-controlled multicentre study. Gut 1999; 45 (Suppl. V): A341.
32. Palme M, Milner PG, Ellis DJ, et al,. A novel gastrointestinal prokinetic, ATI-7505, increased spontaneous bowel movements (Sbms) in a phase II, randomized, placebo-controlled study of patients with chronic idiopathic constipation (CIC). Gastroenterology 2010; 138: S128-9.
33. Cinca R, Chera D, Gruss HJ, et al,. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation-a comparison in a controlled environment. Aliment Pharmacol Ther 2013; 37: 876-86.
34. Sloots CE, Poen AC, Kerstens R, et al,. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759-67.
35. Jaeschke R, Singer J, Guyatt GH,. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
36. Camilleri M, Van Outryve MJ, Beyens G, et al,. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation-follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010; 32: 1113-23.
37. Camilleri M,. Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipation. Therap Adv Gastroenterol 2011; 4: 159-63.
38. Chiarioni G, Whitehead WE, Pezza V, et al,. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006; 130: 657-64.
39. Ioannidis JP,. Why most discovered true associations are inflated. Epidemiology 2008; 19: 640-8.